Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis

ISSN: 1875-5666 (Online)
ISSN: 1566-5240 (Print)

Volume 17, 10 Issues, 2017

Download PDF Flyer

Current Molecular Medicine

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 47th of 124 in Medicine, Research & Experimental

Submit Abstracts Online Submit Manuscripts Online

David W. Li
College of Medicine
University of Nebraska Medical Center
Omaha, NE

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.912
5 - Year: 3.478

Review Article

Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis

Current Molecular Medicine, 14(4): 423-431.

Author(s): J. Abdi, J. Garssen and F Redegeld.

Affiliation: Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, P.O. Box 80082, 3508 TB Utrecht, The Netherlands.


Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may induce cell growth and proliferation or promote cell death. In fact, our current knowledge of Toll-like receptor function has gone beyond their main function as triggers of innate and adaptive immune responses. Considering the essential role of bone marrow microenvironment components in myeloma tumor expansion, survival, invasion and drug resistance, TLR triggering may contribute to adhesion-induced or de novo drug resistance of MM cells. Future preclinical and clinical studies are needed to address if TLRs can be exploited as novel therapeutic targets for MM.


Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 4
First Page: 423
Last Page: 431
Page Count: 9
DOI: 10.2174/1566524014666140414204100
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science